Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
AbstractOral darolutamide (Nubeqa ™) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). In the pivotal multinational, phase 3 ARAMIS trial in men with nmCRPC, relative to placebo plus ongoing androgen de privation therapy (ADT), darolutamide (+ ADT) significantly prolonged metastasis-free survival (MFS) at the time of the primary analysis and overall survival (OS) at the time of the final OS analysis and was generally well tolerated in extended follow-up. Albeit long-term data from the real-wor...
Source: Targeted Oncology - November 25, 2020 Category: Cancer & Oncology Source Type: research
Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis
ConclusionsThis meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments. (Source: Targeted Oncology)
Source: Targeted Oncology - November 22, 2020 Category: Cancer & Oncology Source Type: research
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
ConclusionResults from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced/metastatic melanoma, particularlyBRAF- andNRAS-mutated tumors, at clinically relevant doses associated with pERK inhibition in peripheral blood mononuclear cells.Trial RegistrationClinicalTrials.gov, NCT00982865 (Source: Targeted Oncology)
Source: Targeted Oncology - November 19, 2020 Category: Cancer & Oncology Source Type: research
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
ConclusionsThis analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians.PfizerNCT01740427. (Source: Targeted Oncology)
Source: Targeted Oncology - November 19, 2020 Category: Cancer & Oncology Source Type: research
SB8: A Bevacizumab Biosimilar
AbstractSB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles. (Source: Targeted Oncology)
Source: Targeted Oncology - November 18, 2020 Category: Cancer & Oncology Source Type: research
Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - November 17, 2020 Category: Cancer & Oncology Source Type: research
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Discussion, right column, second paragraph. (Source: Targeted Oncology)
Source: Targeted Oncology - November 12, 2020 Category: Cancer & Oncology Source Type: research
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
ConclusionsBased on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedule and the RP2D was defined as 60 mg bid.Trial RegistrationClinicalTrials.gov, NCT00982865. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2020 Category: Cancer & Oncology Source Type: research
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE ‑2 Study
The listing of the author names and affiliations, which previously read. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2020 Category: Cancer & Oncology Source Type: research
Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
ConclusionsSymptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - November 9, 2020 Category: Cancer & Oncology Source Type: research
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
ConclusionsEverolimus reduces the risk of disease progression in hormone receptor (+) MBC. In patients with HER2 (+) disease, the benefit is limited for those with hormone receptor ( −) disease. Given the approval and use of newer drugs in MBC, clinical trials and real-world data are needed to confirm the benefit of everolimus and define the best treatment sequence strategy to adopt in that setting. (Source: Targeted Oncology)
Source: Targeted Oncology - November 5, 2020 Category: Cancer & Oncology Source Type: research
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
ConclusionsOur tailored next-generation sequencing assay coupled with a comprehensive analysis may improve therapeutic management in a significant number of patients with melanoma. Updating such a panel and implementing multi-omic approaches will further enhance patients ’ clinical management. (Source: Targeted Oncology)
Source: Targeted Oncology - November 5, 2020 Category: Cancer & Oncology Source Type: research
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
An Online First version of this article was made available online athttps://link.springer.com/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were subsequently identified in the article, and the following corrections should be noted. (Source: Targeted Oncology)
Source: Targeted Oncology - October 28, 2020 Category: Cancer & Oncology Source Type: research
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Source: Targeted Oncology)
Source: Targeted Oncology - October 27, 2020 Category: Cancer & Oncology Source Type: research
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
ConclusionsCetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC withoutKRAS, NRAS, or BRAF mutations.Clinical Trial RegistrationNCT02693535 (26 February, 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - October 22, 2020 Category: Cancer & Oncology Source Type: research
